Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure: SUMMIT CMR Substudy

What Was Tested

This randomized controlled trial paper looks at Tirzepatide.

Obesity is a known risk factor for heart failure with preserved ejection fraction (HFpEF) and is considered a distinct phenotype with more concentric remodeling.

Who Took Part

The abstract describes 175 patients taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

A total of 106 patients completed the CMR and had adequate image quality for analysis of LV and left atrial structure and function and paracardiac (epicardial plus pericardial) adipose tissue at both baseline and 52 weeks.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The patients were allocated by chance, so the Tirzepatide group and the comparison group should start out alike.

Blinding on both sides kept the patients and researchers unaware of who received Tirzepatide.

A placebo (an inactive look-alike) gave the Tirzepatide group a baseline to be compared against.

The prespecified primary endpoint of this substudy was between-group changes in LV mass.

What Was Measured

PubMed files the paper under topics including Heart Failure, Adipose Tissue, Obesity, Magnetic Resonance Imaging, Cine, Heart Ventricles, Stroke Volume and Tirzepatide.

Author keywords: GLP1 agonist, HFpEF, LV mass and cardiac MRI.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Tirzepatide in 175 patients.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2025 (Journal of the American College of Cardiology), a journal based in United States.

More context: the Tirzepatide compound page.